Corbus Pharmaceuticals Holding Stock Today
| CRBP Stock | USD 16.73 0.65 4.04% |
Performance0 of 100
| Odds Of DistressOver 85
|
Corbus Pharmaceuticals is selling at 16.73 as of the 21st of November 2024; that is 4.04 percent increase since the beginning of the trading day. The stock's last reported lowest price was 16.08. Corbus Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Corbus Pharmaceuticals Holding are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of November 2014 | Category Healthcare | Classification Health Care |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Corbus Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 12.18 M outstanding shares of which 2.38 M shares are currently shorted by private and institutional investors with about 5.39 trading days to cover. More on Corbus Pharmaceuticals Holding
Moving together with Corbus Stock
| 0.85 | VRAX | Virax Biolabs Group | PairCorr |
| 0.71 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.68 | DYN | Dyne Therapeutics | PairCorr |
| 0.71 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Corbus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Corbus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and Director | Yuval Cohen | ||||
| Thematic Idea | Cannabis (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cannabis, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCorbus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corbus Pharmaceuticals' financial leverage. It provides some insight into what part of Corbus Pharmaceuticals' total assets is financed by creditors.
| |||||
Corbus Pharmaceuticals Holding (CRBP) is traded on NASDAQ Exchange in USA. It is located in 500 River Ridge Drive, Norwood, MA, United States, 02062 and employs 19 people. Corbus Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 195.85 M. Corbus Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.18 M outstanding shares of which 2.38 M shares are currently shorted by private and institutional investors with about 5.39 trading days to cover.
Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Corbus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Corbus Pharmaceuticals Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corbus Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corbus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Corbus Pharmaceuticals Holding as this could imply that something significant has changed or is about to change at the company.
Check Corbus Ownership Details
Corbus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Woodline Partners Lp | 2024-06-30 | 249.3 K | |
| Millennium Management Llc | 2024-06-30 | 241.6 K | |
| Geode Capital Management, Llc | 2024-06-30 | 231.1 K | |
| Sio Capital Management, Llc | 2024-06-30 | 225.2 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 221.2 K | |
| Point72 Asset Management, L.p. | 2024-06-30 | 216.5 K | |
| Avidity Partners Management Lp | 2024-06-30 | 215.6 K | |
| Hhg Plc | 2024-06-30 | 203.3 K | |
| Ghost Tree Capital, Llc | 2024-06-30 | 175 K | |
| Cormorant Asset Management, Llc | 2024-06-30 | 2 M | |
| Blackrock Inc | 2024-06-30 | 761.4 K |
Corbus Pharmaceuticals Historical Income Statement
Corbus Stock Against Markets
Corbus Pharmaceuticals Corporate Management
| MD MA | Chief Officer | Profile | |
| Christina Bertsch | Head Resources | Profile | |
| CPA MBA | Chief Officer | Profile | |
| Rachael Brake | Chief Officer | Profile | |
| Lindsey Smith | Head Advocacy | Profile |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.